Press Room

Event

CRS 2026 Annual Meeting

Start

Monday, July 06, 2026

End

Thursday, July 09, 2026

Location: Lisbon, Portugal

Hovione is presenting at the CRS 2026 Annual Meeting, taking place in Lisbon, Portugal. The conference will explore groundbreaking advancements and transformative ideas in controlled release science and technology. Join the Hovione team for an inspiring week of insightful presentations, engaging discussions, and unparalleled networking opportunities with leading experts and innovators from around the world.

Schedule a meeting. Let’s discuss your project together.

Don’t miss the chance to speak with our experts and learn how we are advancing a differentiated offering in Biologics and Complex Injectables, from early development through to cGMP supply.

HOVIONE TECHNICAL FORUM

Rational Formulation Strategies for High Concentration Subcutaneous Biologics: From Innovative Excipients to Spray Dried Drug Product Suspensions

July 7, 9:00–10:00 AM (WEST)

Joana Cristóvão, Ph.D. | R&D, Analytical Senior Manager
Inês Matos, Ph.D.| R&D, Inhalation & Advanced Drug Delivery Manager

Innovative formulation and manufacturing strategies are accelerating the shift from intravenous (IV) to patient-friendly subcutaneous (SC) delivery of biologics. This transition is driven by strong patient preference, reduced healthcare burden, and the opportunity for at-home administration. But challenges remain, especially for high-dose biologics.

At the Hovione Technical Forum, in a single session, two complementary presentations will showcase how advanced formulation science and particle engineering are expanding the possibilities for efficient, scalable, and patient-centric biologic therapies:

Learn more about novel excipient design strategies to reduce viscosity and enhance stability in high-concentration liquid formulations
Get insights on spray drying as an enabling technology for biologics, unlocking new solid-state and ultra-concentrated formats

ORAL PRESENTATION

Addressing Nasal Delivery Challenges: Integrated Formulation and Device Strategies for Predictive Performance

July 8, 2:53 PM - 3:16 PM WEST

Patrícia Henriques, Ph.D. | Scientist, Inhalation and Advanced Drug Delivery

Nasal powder delivery is emerging as a versatile platform for both local and systemic administration, as well as nose-to-brain applications. This presentation will highlight an integrated, evidence-driven development approach combining formulation design, particle engineering, device selection, and translational in vitro tools to enable targeted deposition and improved bioavailability.

Starting from a deep understanding of the API, the presentation will address excipient selection, process development, and particle engineering approaches, together with fit-for-purpose analytical and device considerations. Case studies will illustrate how these elements work together to address key development challenges, including dose constraints and the delivery of complex or poorly soluble therapeutics, supporting robust and performance-driven nasal powder products.

POSTERS & Poster Presenter

(113) Looking Beyond Aerodynamics: Evaluation of Fluticasone Furoate via Dissolution and Permeation using Lung ALIs
Beatriz Gamelas, M.Sc.| Ph.D. Candidate, Analytical Development
Learn more about the importance of developing robust dissolution and permeation methods to study drug bioavailability and ensure consistent performance of orally inhaled drug products (OIDPs) for early formulation screening
(132) Why Model Structure Matters: Translatability Across Inhalation PBPK Frameworks
Filipa Ferreira, Pharm.D., Ph.D. | Senior Scientist II, Translational Lead | Innovation
Learn how inhalation PBPK model structure influences the prediction of pulmonary and systemic drug exposure, and why regional lung deposition and permeability are key drivers of pharmacokinetic outcomes.
(502) Innovative Synthetic Sugars for Stable, Low-viscosity High-Concentration Biologic Formulations
Joana Cristóvão, Ph.D. | R&D, Analytical Senior Manager
High-concentration biologics don't have to be viscous. With this poster, learn how Hovione Synthetic Sugars are solving one of the biggest challenges in subcutaneous biologic delivery.
(655) Optimizing CRISPR/Cas9 Polymeric Nanoparticle Formulations: From In Silico Insights to Microfluidics and Stability Strategies
Andreia Sofia Pereira | Student, Inhalation and Advanced Drug Delivery
Neurological disorders are the leading global cause of disability, driving an urgent demand for brain regeneration therapies. Learn how Hovione is contributing to the @REGENERAR project, optimizing both the formulation and manufacturing process of engineered nanoparticles (NPs) to reprogram non-neuronal cells for neuronal regeneration.

Ask us how we’re advancing more patient centric therapies through proprietary excipients, such as synthetic sugars, and spray dried approaches that unlock alternative dosage forms.

Also in the Press Room

See All

The investment includes both continuous and batch tableting capabilities, as well as connect spray drying with tablet production at its East Windsor campus. Hovione, a Portugal-based contract development and manufacturing organization (CDMO), plans to install a continuous tableting line at its East Windsor, New Jersey campus, adding drug product manufacturing capacity and an integrated pathway from amorphous solid dispersion production through commercial tablet manufacturing. The $35 million investment will bring the first ConsiGma CDC Flex system to Hovione’s recently opened 89 Twin Rivers facility. The line is expected to be commissioned in late 2027 and will support both continuous and batch operation at throughputs ranging from 1 to 200 kilograms per hour, according to the announcement. The system will allow customers to use the same equipment for development, clinical, and commercial production, with formulation development possible using as little as 1.5 kilograms of material. Hovione said the line will also be equipped for containment to 1 microgram per cubic meter to support the handling of highly potent compounds. The new capability will also connect Hovione’s spray-drying operations with tablet manufacturing at the East Windsor campus. The company recently opened a 31,000-square-foot facility at the campus with two commercial-scale spray dryers for manufacturing amorphous solid dispersions (ASDs), completing a $100 million investment in its New Jersey operations. Hovione said the integrated setup will allow customers to move from formulation and particle engineering through tablet production under one quality system, reducing technology transfer requirements and eliminating traditional scale-up between development and commercial production. The ConsiGma CDC Flex platform was jointly developed with GEA as part of a collaboration that began in 2022, the company said. The system incorporates automated process controls and process analytical technology for real-time monitoring during production. Hovione already operates continuous tableting technology at its Loures, Portugal site. In August, the company completed a more than €40 million expansion of its tablet development and manufacturing center there, adding a second commercial-scale tableting line and increasing the center's manufacturing area by 25%. The East Windsor installation will extend Hovione’s continuous tableting capabilities to the U.S. and expand its integrated drug development and manufacturing services for oral solid dosage products. Read the full article at Pharma Manufacturing

Press Clipping

Pharma Manufacturing, 6 October 2026

Hovione to add $35M continuous tableting line at New Jersey site

Oct 06, 2026

Hovione, a globally integrated pharmaceutical contract development and manufacturing organisation (CDMO), will commission the world’s first ConsiGma CDC flex – a next generation continuous tableting line – at its East Windsor, New Jersey (USA) campus in late 2027. The line will be installed at 89 Twin Rivers, Hovione’s recently opened facility, expanding the company’s drug product capabilities and strengthening its integrated pharmaceutical development and manufacturing hub in the US. CDC ConsiGma flex system The project represents an investment of $35 million. Once installed it will create an integrated pathway from amorphous solid dispersion manufacturing via spray drying through commercial tablet production. The new flex will operate in continuous or batch modes across a very broad throughput range (from one to 200 kg/h). Customers will be able to develop a formulation using small quantities of material, down to 1.5 kg, and then run from very small clinical batches to large commercial batches using the same equipment. This is enabled by specialised design within the flex to effectively switch between continuous blenders of various sizes. Additionally, the line will be installed for containment to 1 µg/m³, supporting highly potent compounds. Continuous tableting is reshaping manufacturing of oral solid dosage medicines and is well suited to programmes in which speed, supply resilience and efficient use of high-value active pharmaceutical ingredients (APIs) are priorities. Inline process analytical technology (PAT) and automated controls also provide real-time quality monitoring. In parallel, the 2022 adoption of ICH Q13 regulatory framework, guidance specifically for continuous manufacturing of drug substances and drug products, provides harmonisation across the US, Europe and Japan. As of 2024, 17 products manufactured under the international guidance have been approved by the US Food and Drug Administration (FDA) alone. Developed jointly with GEA, the ConsiGma CDC flex platform also incorporates SimpleCT, a suite of automation and control tools with smart interfaces that supports a single process from development to commercial supply. Designed for versatility and ease of use, these innovative developments simplify operation, improve efficiency and containment, and enhance operator safety. Read the full article at Pharma Press UK

Press Clipping

Pharma Press Global, 6 October 2026

Hovione to commission world’s first ConsiGma CDC flex, bringing next-generation continuous tableting to the US

Oct 06, 2026

Key Takeaways Commissioning a US-based ConsiGma CDC Flex line enables end-to-end spray drying-to-tablet manufacture within a single site and quality system, reducing comparability and technology-transfer burdens. Elimination of conventional scale-up is enabled by using the same equipment from early development through commercial supply, minimizing engineering runs and conserving scarce API. Operational flexibility spans batch or continuous modes and 1–200 kg/h throughput, with scale adjustment achieved by switching continuous blenders rather than replatforming processes. High-containment design to 1 µg/m³ expands suitability for highly potent oral solid-dose programs while maintaining integrated development-to-commercial workflows. Regulatory momentum for continuous manufacturing is supported by ICH Q13 harmonization, increasing FDA approvals, and platforms leveraging inline PAT and automated control suites for real-time quality assurance. Hovione announced on Oct. 5, 2026, that it will commission the ConsiGma CDC Flex, a next-generation continuous direct compression tableting platform jointly developed with GEA. The investment is designed to link amorphous solid dispersion manufacturing via spray drying with commercial tablet production at a single US site operating under one quality system. The line will run in either continuous or batch mode at throughputs from 1 to 200 kg/h. Formulation development can begin with as little as 1.5 kg of material, and the same equipment can then support everything from very small clinical batches to large commercial runs, enabled by a design that allows the system to switch between continuous blenders of different sizes. The installation will also be contained to 1 µg/m³ to accommodate highly potent compounds. "Hovione will be the first company in the world to offer the ConsiGma® CDC Flex, bringing this next-generation technology with unprecedented flexibility, simplicity and cost-efficiency in continuous tableting," said Marco Gil and António Almeida, co-CEOs, Hovione, said in a press release. "This investment also advances our strategy of building integrated capabilities close to customers in key markets. By adding this new line at East Windsor, we are broadening access to this technology in the U.S. and giving customers a more direct and accelerated path for developing and commercializing complex oral medicines." What Does a Single Development-To-Commercial Line Change? For formulators and process engineers, the most consequential claim is the removal of traditional scale-up. Moving a process from development equipment to commercial equipment typically requires engineering runs, bridging work, and consumption of scarce API, all of which weigh heavily on early programs with limited material. "Installing the CDC Flex at 89 Twin Rivers makes continuous tableting part of an integrated US development and manufacturing workflow," said David Basile, Vice President of Technical Operations, Hovione, in the press release. "Customers can move from formulation and particle engineering to commercial tablets with one Hovione team and one quality system, eliminating traditional scale-up while gaining greater production flexibility, process control and supply continuity." Co-locating spray drying and tableting is also significant because amorphous solid dispersions remain a primary solubility-enhancement route for poorly soluble molecules, and transferring intermediates between sites or vendors adds technology transfer and comparability burdens. The new line builds on the company's earlier US expansion; Hovione recently completed a $100 million investment to bolster US capacity in particle design, amorphous solid dispersions via spray drying, and batch and continuous tableting. How Is the Regulatory Environment Shaping Continuous Tableting Adoption? The company points to the 2022 adoption of ICH Q13, which provides harmonized guidance for continuous manufacturing of drug substances and drug products across the US, Europe, and Japan. Hovione reports that, as of 2024, FDA alone had approved 17 products manufactured under the guidance. Speaking on ICH Q13, FDA's Kelley Burridge, PhD, "Perceived barriers to continuous manufacturing have been falling one by one," and noted an FDA publication showing faster approval times for products with continuous manufacturing elements than for comparable batch products. The platform incorporates inline process analytical technology and automated controls for real-time quality monitoring, along with SimpleCT, an automation and control suite intended to support a single process from development through commercial supply. For sponsors weighing supply resilience and regional sourcing, the East Windsor installation extends a capability that Hovione says only it currently offers as a contract development and manufacturing organization. Read the full article at PharmTech.com

Press Clipping

PharmTech, 5 October 2026